Zymeworks: Leader In Bispecifics Space Makes Substantial Headway [Seeking Alpha]
Zymeworks Inc. (ZYME)
Last zymeworks inc. earnings: 3/2 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.zymeworks.com/overview
Company Research
Source: Seeking Alpha
Zymeworks: Leader In Bispecifics Space Makes Substantial Headway Summary Shares have nearly doubled since my initial recommendation to buy the dip in February of last year. I provide a recap of the bullish thesis and recent events. Zymeworks is making a name for itself in the bispecifics space with 9 active partnerships, and remains eligible for up to $8 billion in milestone payments plus royalties. Clinical catalysts in the medium term for wholly owned assets could serve to create significant value for shareholders. Zymeworks remains a Buy. Risk factors include the crowded nature of the HER2 space, disappointing data and negative developments with collaborations. Shares of Zymeworks ( ZYME I suggested my December article The company's first-quarter 2019 report served as a reminder that I needed to revisit this one due to decent progress being made in the clinic and multiple collaborations advancing to inflection points. Figure 1: daily advanced chart (Source: Finviz) When looking at
Show less
Read more
Impact Snapshot
Event Time:
ZYME
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZYME alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZYME alerts
High impacting Zymeworks Inc. news events
Weekly update
A roundup of the hottest topics
ZYME
News
- Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data [Seeking Alpha]Seeking Alpha
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME Accesswire
- ZYME ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Zymeworks Inc.Accesswire
- HER2+ Market to Accelerate Substantially by 2034, Predicts DelveInsight | Key Companies - Zymeworks, Jazz Pharmaceuticals, Ambrx, AnBogen Therapeutics, Enliven Therapeutics, Roche [Yahoo! Finance]Yahoo! Finance
- Levi & Korsinsky Reminds Shareholders of an Investigation into Zymeworks Inc. (ZYME) Regarding Potential Securities Fraud AllegationsAccesswire
ZYME
Earnings
- 3/6/24 - Beat
ZYME
Sec Filings
- 4/4/24 - Form 8-K
- 4/2/24 - Form 4
- 4/2/24 - Form 3
- ZYME's page on the SEC website